156 related articles for article (PubMed ID: 9039064)
1. Reference-based pricing in British Columbia: implications for cardiologists--an analysis.
Boulet AP; Tessier G
Can J Cardiol; 1997 Jan; 13(1):46-51. PubMed ID: 9039064
[TBL] [Abstract][Full Text] [Related]
2. Coverage of drug costs: reference-based pricing.
McGregor M
Can J Cardiol; 1998 May; 14(5):666-8. PubMed ID: 9627520
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.
Schneeweiss S; Soumerai SB; Maclure M; Dormuth C; Walker AM; Glynn RJ
Clin Pharmacol Ther; 2003 Oct; 74(4):388-400. PubMed ID: 14534526
[TBL] [Abstract][Full Text] [Related]
4. Reference-based pricing (RBP) of prescription drugs.
Holbrook A; O'Brien B; Grootendorst P
Can J Cardiol; 1997 Jul; 13(7):689-90. PubMed ID: 9251582
[No Abstract] [Full Text] [Related]
5. Re: AP Boulet, G Tessier. Reference-based pricing in British Columbia: implications for cardiologists--an analysis. 1997; 13:46-51.
Kalant N
Can J Cardiol; 1997 Jul; 13(7):640, 689. PubMed ID: 9251575
[No Abstract] [Full Text] [Related]
6. Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia.
Morgan SG; Agnew JD; Barer ML
Health Policy; 2004 Jun; 68(3):299-307. PubMed ID: 15113641
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.
Schneeweiss S; Walker AM; Glynn RJ; Maclure M; Dormuth C; Soumerai SB
N Engl J Med; 2002 Mar; 346(11):822-9. PubMed ID: 11893794
[TBL] [Abstract][Full Text] [Related]
8. Out-of-pocket and total costs of fixed-dose combination antihypertensives and their components.
Rabbani A; Alexander GC
Am J Hypertens; 2008 May; 21(5):509-13. PubMed ID: 18437141
[TBL] [Abstract][Full Text] [Related]
9. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.
Grootendorst PV; Marshall JK; Holbrook AM; Dolovich LR; O'Brien BJ; Levy AR
Health Serv Res; 2005 Oct; 40(5 Pt 1):1297-317. PubMed ID: 16174135
[TBL] [Abstract][Full Text] [Related]
10. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost.
Fendrick AM; Smith DG; Chernew ME; Shah SN
Am J Manag Care; 2001 Sep; 7(9):861-7. PubMed ID: 11570020
[TBL] [Abstract][Full Text] [Related]
11. A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia.
Grootendorst P; Stewart D
Health Econ; 2006 Jul; 15(7):735-42. PubMed ID: 16498702
[TBL] [Abstract][Full Text] [Related]
12. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
13. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia.
Marshall JK; Grootendorst PV; O'Brien BJ; Dolovich LR; Holbrook AM; Levy AR
CMAJ; 2002 Jun; 166(13):1655-62. PubMed ID: 12126319
[TBL] [Abstract][Full Text] [Related]
14. Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals.
Andersson K; Bergström G; Petzold MG; Carlsten A
Health Policy; 2007 May; 81(2-3):376-84. PubMed ID: 16945449
[TBL] [Abstract][Full Text] [Related]
15. Effects of managerial intervention on drug utilization pattern at King Chulalongkorn Memorial Hospital.
Limpanasithikul W; Wangsaturaka D; Nantawan P; Itthipanichapong C; Thamaree S; Wittayalertpanya S; Ketcharoen A; Taworn N; Kemsri W; Kusolsomboon T; Tangphao O
J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S336-43. PubMed ID: 12188432
[TBL] [Abstract][Full Text] [Related]
16. [Medical problems associated with the national reference pricing system in Hungary].
Kerpel-Fronius S
Orv Hetil; 2004 Apr; 145(17):913-8. PubMed ID: 15170969
[TBL] [Abstract][Full Text] [Related]
17. Out-of-pocket costs to users: medicine options for hypertension.
Arredondo A
Am J Hypertens; 2008 May; 21(5):492. PubMed ID: 18437138
[No Abstract] [Full Text] [Related]
18. Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence.
Kaló Z; Muszbek N; Bodrogi J; Bidló J
Health Policy; 2007 Mar; 80(3):402-12. PubMed ID: 16730848
[TBL] [Abstract][Full Text] [Related]
19. Evaluating reference-based pricing: initial findings and prospects.
Narine L; Senathirajah M; Smith T
CMAJ; 1999 Aug; 161(3):286-8. PubMed ID: 10463052
[TBL] [Abstract][Full Text] [Related]
20. Points to consider about prescription drug prices: an overview of federal policy and pricing studies.
Kucukarslan S; Hakim Z; Sullivan D; Taylor S; Grauer D; Haugtvedt C; Zgarrick D
Clin Ther; 1993; 15(4):726-38. PubMed ID: 8221823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
